- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Isaac Galatzer-Levy Explains How a Predictive Algorithm Uses Machine Learning to Predict PTSD Risk
Isaac Galatzer-Levy, PhD, assistant professor in psychiatry and bioinformatics, NYU School of Medicine, and vice president of clinical and computational neuroscience, AiCure, describes how his team built a predictive algorithm using machine learning to predict the development of posttraumatic stress disorder (PTSD).
Isaac Galatzer-Levy, PhD, assistant professor in psychiatry and bioinformatics, NYU School of Medicine, and vice president of clinical and computational neuroscience, AiCure, describes how his team built a predictive algorithm using machine learning to predict the development of posttraumatic stress disorder (PTSD).
Transcript
How does the predictive algorithm constructed by your lab use machine learning to predict PTSD risk?
So, PTSD risk is really dependent on multiple factors. There’s many different things that can cause a deleterious outcome after trauma. And even the outcomes that you have vary between individuals, whether it’s PTSD, depression, problems with sleep, problems with memory, problems with arousal. So we constructed an algorithm that uses electronic medical records and simple information about the patient’s objective distress to predict how the patient is going to do over the next 12 months.
We built it and validated it in 2 independent data sets. One, the Grady trauma project from Emory Hospital, roughly 220 subjects, and then we validated it in our own sample collected at Bellevue Hospital in New York City. We got a predictive accuracy of roughly 90% for predicting chronic PTSD, and we replicated that independently in the Bellevue data set.
The sources of data include information on immune response, metabolic response, all the early biological changes that are associated with the onset of PTSD and depression that cause changes in things like sleep patterns, memory, arousal.
Cellular Therapies in Lymphoma Bring Hope, but Optimizing Their Use Remains a Challenge
December 10th 2023Recent decades have seen marked improvements in hematological cancer outcomes and an expanded armamentarium of therapies, but novel treatments require updated strategies that are not always easy to fine-tune, according to presenters at the 2023 American Society of Hematology Annual Meeting and Exposition.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
